Neuroendocrine tumours are increasing in incidence. In diffuse cases, which are very common, the question of the most appropriate testament is essential. This paper favors cTACE over DEB-TACE and Y90.

Key points:

• cTACE achieved a significantly longer overall survival in patients with unresectable NELM.
• Patients treated with cTACE showed a prolonged hepatic progression-free survival.
• cTACE, DEB-TACE and Y90 radioembolisation demonstrated comparable safety and toxicity profiles.
• Age >70 years, extrahepatic metastases and tumour burden >50% were identified as negative predictors.
• Propensity score analysis suggests the superiority of cTACE over DEB-TACE and Y90.

Article: Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model

Authors: Minh et al, December 2017, Volume 27, Issue 12, pp 4995–5005